Introduction: There is a lack of data comparing the protease inhibitors (PIs) atazanavir (ATV) and darunavir (DRV) in a real-world setting. This study compared persistence (time to switch/discontinuation) to therapy between ATV-treated and DRV-treated patients with human immunodeficiency virus (HIV). Materials and Methods: Retrospective, observational cohort study using US insurance claims for commercially and Medicaidinsured patients. Patients were aged ]18 years and initiated an ATV-or DRV-based regimen boosted with ritonavir between 7/1/2006 and 3/31/2013, with ]6 months of continuous enrolment prior to and ]3 months of continuous enrolment following initiation; patients were required to have ]1 inpatient or outpatient medical claim with an ICD-9-CM diagnosis code for HIV during that time period of enrolment. Patients with no claims for antiretroviral therapy (ART) any time prior to initiation were considered to be ART-naïve. Time to switch/discontinuation was defined as the number of days from initiation of the regimen until earliest of: (1) a ]30-day continuous gap in therapy in ATV or DRV; (2) a prescription claim for an ART agent that was not part of the initial regimen (with the exception of changes in concomitant nucleoside reverse transcriptase inhibitors or
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